IceCure Medical Ltd. (ICCM) Q4 2024 Earnings Conference Call March 27, 2025 10:00 AM ET Company Participants Conference Call Operator - Call ModeratorMichael Poivieu - Conference Call HostEyal Shamir - CEO, IceCure MedicalRonan Zimmerman - CFO and Chief Operating Officer, IceCure MedicalEduardo (on behalf of Yi Chen) - Representative, HC Wainwright Conference Call Participants Kemp Dolliver - Analyst, Brookline Capital MarketsAnthony Vendetti - Analyst, Maxim Group Conference Call Operator Good morning, and ...

Ermenegildo Zegna (ZGN) Q4 2024 Earnings Call March 27, 2025 09:00 AM ET Company Participants Ermenegildo Zegna - Chairman and CEOGianluca Ambrogio Tagliabue - COO and CFOPaola Durante - Chief of External RelationsAdrien Duverger - Equity Research AssociateOliver Chen - Managing Director - Retail, Luxury, New Platforms Sector HeadMelania Grippo - Equity Research - European Luxury Goods Conference Call Participants Chris Huang - Analyst Operator Good afternoon and good morning, everyone. Thank you for joinin ...

EDAP TMS (EDAP) Q4 2024 Earnings Call March 27, 2025 08:30 AM ET Company Participants John Fraunces - DirectorRyan Rhodes - CEO & DirectorKen Mobeck - Chief Financial Officer Conference Call Participants Michael Sarcone - AnalystNone - AnalystSwayampakula Ramakanth - Managing Director & Senior Equity Analyst Operator and welcome to today's EDAP TMS Fourth Quarter and Full Year twenty twenty four Earnings Conference Call. At this time, all participants are in a listen only mode. Later, you will have the oppo ...

Financial Data and Key Metrics Changes - Revenue totaled $57.5 million, including $43.2 million in interest income, $8.6 million in fees from loans, and $5.2 million from LLC partnership investments [30] - Operating and other costs totaled $97.1 million, resulting in a GAAP net loss of $39.6 million, and a net loss available to common shareholders of $43.9 million after preferred stock dividends [30][31] - Book value per common share at year-end 2024 was $2.64, down from $3.83 in 2023, reflecting a year-over-year change of $1.19 [33][37] Business Line Data and Key Metrics Changes - The non-performing loan book grew year-over-year by $18.3 million to $102.9 million, with $36.3 million in foreclosure status [8][57] - The company funded approximately $134 million in loans, modifications, and extensions during the year [14] - The portfolio included 157 loans with a gross principal value of $377 million and a weighted average contractual interest rate of 12.53% [13] Market Data and Key Metrics Changes - The company has diversified its portfolio across 14 states and the District of Columbia, with over 56% of the principal balance in residential real estate [14] - Multifamily investments generated approximately $5.1 million in revenues, representing a low-risk double-digit yield [20] Company Strategy and Development Direction - The company aims to stabilize its portfolio and position itself for future opportunities by removing non-performing loans and focusing on higher quality loans [9][10] - The company is pursuing a diversification strategy through partnerships, such as with Schemcrete Capital, to enhance its real estate finance capabilities [19][48] - The company plans to selectively build a pipeline of development projects to minimize completion risk and capture market rate earnings [16] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges faced in 2024 due to restrictive bank lending policies and increased construction costs, impacting borrowers' ability to refinance [7] - The company is optimistic about its financial position moving into 2025, with a focus on protecting liquidity and seeking cost-effective capital [22][49] - Management expressed confidence in resolving non-performing loans and expects to generate sufficient cash flow to meet upcoming obligations [25][50] Other Important Information - The company closed on a new credit facility with Needham Bank, providing up to $50 million of committed liquidity [21] - The board declared a quarterly common dividend of $0.05 per share, aligning future dividend declarations with preferred stock payments [46] Q&A Session Summary Question: What is the balance for the loans in non-accrual and foreclosure status as of Q4? - Non-performing loans are approximately $100 million as of December 31st, with significant progress made in resolving them [55] Question: Can you provide specifics on the loan sales? - The total UPB in the loan sale was $55.8 million, comprising 32 loans, with an average realization of around 68% [79][80] Question: What is the status of unfunded loan commitments? - Approximately $54 million in unfunded commitments exists, expected to be funded ratably over the year [72]

Financial Data and Key Metrics Changes - As of December 31, 2024, cash, cash equivalents, and investment-grade securities increased to approximately $9.3 million from $7.3 million as of December 31, 2023 [35] - Revenue for the year ended December 31, 2024, rose to approximately $3.495 million compared to $2.899 million the previous year, driven by license revenue of $1 million from ProLiant and approximately $890,000 from enzymes [35][36] - Loss from operations decreased to approximately $5.901 million in 2024 from $8.230 million in 2023, while net loss was approximately $5.809 million or $0.20 per share compared to a net loss of $6.795 million or $0.24 per share the previous year [39] Business Line Data and Key Metrics Changes - The company emphasized strong revenue performance from non-pharmaceutical products, particularly in alternative proteins and life sciences, with significant progress in recombinant human serum albumin and transferrin [8][14] - Recombinant human serum albumin is on track for commercial launch in 2025, while recombinant transferrin is showing promising results in initial studies [14][15] - The dairy enzyme portfolio achieved a productivity milestone of $425,000 in 2024, with a commercial launch anticipated in late 2025 [18] Market Data and Key Metrics Changes - The human albumin market is approximately $5.6 billion and is expected to grow at double digits annually, driven by increased vaccine production [106] - The DNase I and DNA ligase market is around $900 million, also growing at nearly double digits per year [106] - The non-animal dairy proteins market is valued at $26 billion, indicating significant opportunities for products like alpha-lactalbumin and lactoferrin [107] Company Strategy and Development Direction - The company is focused on near-term product commercialization and technology licensing, aiming to capitalize on immediate revenue opportunities while building a robust biopharmaceutical pipeline [7][10] - Dyadic is strengthening its global impact through partnerships with various organizations, including CEPI and the Gates Foundation, to enhance the development and adoption of its C1 platform for vaccines and treatments [11][25] - The dual-track strategy involves commercializing non-pharmaceutical products while advancing mid- to long-term opportunities in human and animal health [9][24] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growing interest in the company's platforms and products, highlighting the potential for significant revenue generation from upcoming commercial launches [50][112] - The company is committed to ensuring high-quality product specifications before market entry, particularly for recombinant products [56] - Management noted that the current environment has shifted focus towards non-pharmaceutical applications to drive revenues sooner, while still pursuing funding opportunities for pharmaceutical developments [117] Other Important Information - The company received a $3 million grant from the Gates Foundation in November 2024 and a $4.5 million grant from CEPI, which will support the development of recombinant protein vaccines [40][26] - Dyadic is actively pursuing additional grant applications to expand the development of its C1 platform across various vaccine and antibody programs [27][29] Q&A Session Summary Question: Can you explain the Gates Foundation and CEPI grants and their significance? - Management confirmed ongoing interest from both organizations and highlighted the importance of these grants in advancing the company's platform and products [45][46] Question: What is the status of albumin commercialization? - Management indicated that progress is being made towards commercialization, with expectations to launch in early 2025 [52][54] Question: Can you clarify the components of research and development revenue? - Management explained that a significant portion of R&D expenses is covered by grants, allowing for profit margins [61] Question: What is the market size opportunity for various products? - Management provided insights into the market sizes for human albumin, DNase I, and non-animal dairy proteins, emphasizing the high-value segments being targeted [106][107] Question: What is the status of the collaboration with Rubicon in South Africa? - Management noted that Rubicon is currently focusing on animal health vaccines, with potential clinical studies expected by the end of the year [119][120]

Financial Data and Key Metrics Changes - In Q4, the company's ARR growth reached 5%, exceeding the guidance of 4% [10][34] - The ARR outlook for Q4 2026 has been raised from $760 million to $768 million, reflecting an 8% growth [12][48] - Q4 revenue was reported at $254 million, below the guidance of $277 million, primarily due to unbundled SaaS revenue shortfalls [44][45] Business Line Data and Key Metrics Changes - SaaS ACV bookings from new deals increased by 30% year over year to $32 million, marking a quarterly record [27][35] - Bundled SaaS revenue grew 17% year over year, with acceleration from 9% growth in Q1 to 23% growth in Q4 [37][38] Market Data and Key Metrics Changes - The company reported strong AI momentum, with over 90 of the Fortune 500 brands using Verint AI-powered bots [26] - The CX market is in an early stage of AI adoption, with significant growth potential as more customers transition from AI experiments to large-scale deployments [26][29] Company Strategy and Development Direction - The company emphasizes a hybrid cloud approach, allowing customers to layer AI on existing infrastructure without disruption [20][89] - The focus is on delivering strong and differentiated AI business outcomes, which are seen as a key competitive advantage in the CX market [13][17] Management's Comments on Operating Environment and Future Outlook - Management noted that customer confidence is improving, with many moving from small-scale AI experiments to larger deployments [60][66] - The company expects continued ARR growth acceleration, driven by increased AI consumption and customer expansions [29][30] Other Important Information - Cash contribution for fiscal 2025 was reported at $228 million, an increase of 2% year over year [40] - The company has initiated a $200 million stock buyback program and increased its revolver to $500 million [52][53] Q&A Session Summary Question: Customer confidence in buying solutions and deal sizes - Management indicated that customers are moving from small-scale AI experiments to larger deployments, with significant ROI driving this shift [60][62] Question: Impact of pushed unbundled revenue on FY26 guidance - Management clarified that the pushed deals were from existing customers and did not impact the ARR guidance, which remains at 8% growth [68][70] Question: Dynamics of slipped deals and their nature - All slipped deals were from existing customers, with no renewals involved, and the timeline for rollouts has changed [94][96] Question: Channel mix and growth areas - The company is seeing growth in channel partners as they become more capable of selling AI solutions, with a focus on co-selling [100][104] Question: Macro concerns from customers - Management noted that customers are hesitant to undertake infrastructure projects but are increasingly willing to invest in AI solutions that provide tangible results [108][110] Question: Competitive market dynamics and market share - Management believes the company is gaining market share in the CX automation market, driven by its bot strategy and strong customer outcomes [122][126]

Petco Health and Wellness Company (WOOF) Q4 2025 Earnings Call March 27, 2025 02:46 AM ET Company Participants Tina Romani - Investor RelationsJoel Anderson - CEOSabrina Simmons - CFOSteven Forbes - Senior Managing DirectorDavid Lance Hays - Senior Due Diligence Consultant & Senior Assistant Vice PresidentSeth Basham - MD - Equity Research Conference Call Participants Steven Zaccone - AnalystMichael Lasser - Equity Research Analyst - Hardlines, Broadlines & Food RetailOliver Wintermantel - AnalystSimeon Gut ...

Xia Yangfang Ladies and gentlemen, media, friends from the media, good morning. Welcome to the 2024 Annual Results Presentation of China Merchants Bank. I am Xia Yangfang, General Manager of the Office of the Board Directors. CMB has announced our 2024 annual results on Tuesday evening. Today's event is being conducted both off-line and via live webcast. I would like to introduce the participants of today's event. They are Mr. . Miao Jianmin, Chairman of the Board, Mr. . Wang Liang, President and CEO, Mr. . ...

MillerKnoll (MLKN) Q3 2025 Earnings Call March 26, 2025 11:33 PM ET Company Participants Wendy Watson - Vice President of IR and Corporate CommunicationsAndi Owen - Chief Executive OfficerJeff Stutz - Chief Financial OfficerDebbie Propst - President of Global RetailJohn Michael - President of North America Contract Conference Call Participants Brian Gordon - Senior Research AnalystGregory Burns - AnalystAlex Fuhrman - Senior Research AnalystReuben Garner - Equity Research Analyst Operator Good evening, and ...

Financial Data and Key Metrics Changes - In Q1 2025, the company reported revenue of approximately $2.37 billion, growing 1.3% year over year on a constant currency basis, exceeding expectations [21][30] - Non-GAAP operating income was $322 million, with a margin of 13.6%, an increase of 30 basis points from Q1 last year [24] - Non-GAAP net income was $188 million, reflecting a nearly 9% increase year over year, with non-GAAP diluted EPS at $2.79 [25][26] - Adjusted free cash flow was a use of $40 million, an improvement of $41 million from last year [27] Business Line Data and Key Metrics Changes - Revenue from retail, travel, and e-commerce clients grew 4% year over year, led by travel clients [22] - Revenue from banking, financial services, and insurance grew 3% [22] - The tech vertical grew about 1%, primarily driven by consumer electronics, while healthcare and media sectors were largely flat year on year [23] Market Data and Key Metrics Changes - The company has no exposure to US government contracts at this time [23] - The demand environment in Q1 was solid, with a focus on consolidation opportunities and cross-selling [9][31] Company Strategy and Development Direction - The company’s long-term growth strategy focuses on integrated AI solutions and expanding the value provided to clients [10][16] - The deployment of Gen AI solutions is a key part of the strategy, with thousands of seats now deployed across enterprise clients [13][57] - The company aims to grow its share of wallet and market through a broader array of business services [18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in ongoing revenue, margin, and cash flow growth for the remainder of the year [8] - The macro environment is viewed as muted, with strong performance in Asia Pacific and Europe [110] - The company expects to generate mid-single-digit growth in the long term [32] Other Important Information - The company returned approximately $48 million to shareholders in Q1, including share repurchases and dividends [28] - The company is focused on maintaining investment-grade principles while supporting its dividend [40] Q&A Session Summary Question: Commentary on consumer electronics vertical - Management noted that the company is taking market share in consumer electronics, with stability observed in the sector [46][48] Question: AI suite usage and revenue generation - The IXLO suite is being deployed internally and commercially, with thousands of seats already in use, expected to generate revenue [55][57] Question: Gen AI impact on revenue growth - Management indicated that Gen AI is pervasive across solutions, contributing positively to revenue growth despite initial challenges [63][76] Question: Guidance and margin expectations - Management maintained a conservative approach to guidance, with some ramp costs affecting Q2 margins [81] Question: Debt positioning and refinancing plans - The company is actively engaged in discussions to refinance a €700 million seller's note due in September, aiming to maintain leverage [105][107] Question: Macro trends and booking momentum - The macro environment is muted, but bookings are strong in Asia Pacific and Europe, with a focus on offshore delivery [110][112]